Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey
Abstract To reveal waning humoral immunity after second dose BNT162b2 vaccinations in a rural Japanese community and determine factors affecting antibody titers. We aimed to report Immunoglobulin G (IgG) antibody against the SARS-CoV-2 spike (S1) protein levels and neutralizing activity in a large s...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-11-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-21797-x |
| _version_ | 1811230476568887296 |
|---|---|
| author | Yurie Kobashi Takeshi Kawamura Yuzo Shimazu Tianchen Zhao Akira Sugiyama Aya Nakayama Yudai Kaneko Yoshitaka Nishikawa Fumiya Omata Morihito Takita Chika Yamamoto Makoto Yoshida Makoto Kosaka Anju Murayama Sota Sugiura Manato Tanaka Moe Kawashima Yuna Uchi Joji Shindo Tomoyoshi Oikawa Kenji Shibuya Tatsuhiko Kodama Masaharu Tsubokura |
| author_facet | Yurie Kobashi Takeshi Kawamura Yuzo Shimazu Tianchen Zhao Akira Sugiyama Aya Nakayama Yudai Kaneko Yoshitaka Nishikawa Fumiya Omata Morihito Takita Chika Yamamoto Makoto Yoshida Makoto Kosaka Anju Murayama Sota Sugiura Manato Tanaka Moe Kawashima Yuna Uchi Joji Shindo Tomoyoshi Oikawa Kenji Shibuya Tatsuhiko Kodama Masaharu Tsubokura |
| author_sort | Yurie Kobashi |
| collection | DOAJ |
| description | Abstract To reveal waning humoral immunity after second dose BNT162b2 vaccinations in a rural Japanese community and determine factors affecting antibody titers. We aimed to report Immunoglobulin G (IgG) antibody against the SARS-CoV-2 spike (S1) protein levels and neutralizing activity in a large scale community based cohort. Methods: Participants in the observational cross-sectional study received a second dose of vaccination with BNT162b2 (Pfizer/BioNTech) and were not previously infected with COVID-19. Questionnaire-collected data on sex, age, adverse vaccine reactions, and medical history was obtained. Results: Data from 2496 participants revealed that older age groups reached a low antibody titer 90–120 days after the second vaccination. Neutralizing activity decreased with age; 35 (13.3%) of those aged ≥ 80 years had neutralizing activity under the cut-off value. Neutralizing activity > 179 days from the second vaccination was 11.6% compared to that at < 60 days from the second vaccination. Significantly lower IgG antibody titers and neutralizing activity were associated with age, male sex, increased time from second vaccination, smoking, steroids, immunosuppression, and comorbidities. Conclusions: Antibody titer decreased substantially over time. Susceptible populations, older people, men, smokers, steroid users, immunosuppression users, and people with three or more comorbidities may require a special protection strategy. |
| first_indexed | 2024-04-12T10:29:57Z |
| format | Article |
| id | doaj.art-f7c7d0cd7d3249cca6a49b0960cad7ab |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-12T10:29:57Z |
| publishDate | 2022-11-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-f7c7d0cd7d3249cca6a49b0960cad7ab2022-12-22T03:36:53ZengNature PortfolioScientific Reports2045-23222022-11-0112111010.1038/s41598-022-21797-xHumoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community SurveyYurie Kobashi0Takeshi Kawamura1Yuzo Shimazu2Tianchen Zhao3Akira Sugiyama4Aya Nakayama5Yudai Kaneko6Yoshitaka Nishikawa7Fumiya Omata8Morihito Takita9Chika Yamamoto10Makoto Yoshida11Makoto Kosaka12Anju Murayama13Sota Sugiura14Manato Tanaka15Moe Kawashima16Yuna Uchi17Joji Shindo18Tomoyoshi Oikawa19Kenji Shibuya20Tatsuhiko Kodama21Masaharu Tsubokura22Department of Radiation Health Management, Fukushima Medical University School of MedicineIsotope Science Center, The University of TokyoDepartment of Radiation Health Management, Fukushima Medical University School of MedicineDepartment of Radiation Health Management, Fukushima Medical University School of MedicineIsotope Science Center, The University of TokyoIsotope Science Center, The University of TokyoLaboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of TokyoDepartment of Internal Medicine, Hirata Central HospitalDepartment of Internal Medicine, Hirata Central HospitalDepartment of Radiation Health Management, Fukushima Medical University School of MedicineDepartment of Radiation Health Management, Fukushima Medical University School of MedicineMedical Governance Research InstituteMedical Governance Research InstituteMedical Governance Research InstituteMedical Governance Research InstituteMedical Governance Research InstituteDepartment of Radiation Health Management, Fukushima Medical University School of MedicineDepartment of Radiation Health Management, Fukushima Medical University School of MedicineShindo ClinicMinamisoma Municipal General HospitalDepartment of Radiation Health Management, Fukushima Medical University School of MedicineLaboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of TokyoDepartment of Radiation Health Management, Fukushima Medical University School of MedicineAbstract To reveal waning humoral immunity after second dose BNT162b2 vaccinations in a rural Japanese community and determine factors affecting antibody titers. We aimed to report Immunoglobulin G (IgG) antibody against the SARS-CoV-2 spike (S1) protein levels and neutralizing activity in a large scale community based cohort. Methods: Participants in the observational cross-sectional study received a second dose of vaccination with BNT162b2 (Pfizer/BioNTech) and were not previously infected with COVID-19. Questionnaire-collected data on sex, age, adverse vaccine reactions, and medical history was obtained. Results: Data from 2496 participants revealed that older age groups reached a low antibody titer 90–120 days after the second vaccination. Neutralizing activity decreased with age; 35 (13.3%) of those aged ≥ 80 years had neutralizing activity under the cut-off value. Neutralizing activity > 179 days from the second vaccination was 11.6% compared to that at < 60 days from the second vaccination. Significantly lower IgG antibody titers and neutralizing activity were associated with age, male sex, increased time from second vaccination, smoking, steroids, immunosuppression, and comorbidities. Conclusions: Antibody titer decreased substantially over time. Susceptible populations, older people, men, smokers, steroid users, immunosuppression users, and people with three or more comorbidities may require a special protection strategy.https://doi.org/10.1038/s41598-022-21797-x |
| spellingShingle | Yurie Kobashi Takeshi Kawamura Yuzo Shimazu Tianchen Zhao Akira Sugiyama Aya Nakayama Yudai Kaneko Yoshitaka Nishikawa Fumiya Omata Morihito Takita Chika Yamamoto Makoto Yoshida Makoto Kosaka Anju Murayama Sota Sugiura Manato Tanaka Moe Kawashima Yuna Uchi Joji Shindo Tomoyoshi Oikawa Kenji Shibuya Tatsuhiko Kodama Masaharu Tsubokura Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey Scientific Reports |
| title | Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey |
| title_full | Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey |
| title_fullStr | Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey |
| title_full_unstemmed | Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey |
| title_short | Humoral immunity after second dose of BNT162b2 vaccine in Japanese communities: an observational cross-sectional study, Fukushima Vaccination Community Survey |
| title_sort | humoral immunity after second dose of bnt162b2 vaccine in japanese communities an observational cross sectional study fukushima vaccination community survey |
| url | https://doi.org/10.1038/s41598-022-21797-x |
| work_keys_str_mv | AT yuriekobashi humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT takeshikawamura humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT yuzoshimazu humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT tianchenzhao humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT akirasugiyama humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT ayanakayama humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT yudaikaneko humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT yoshitakanishikawa humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT fumiyaomata humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT morihitotakita humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT chikayamamoto humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT makotoyoshida humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT makotokosaka humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT anjumurayama humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT sotasugiura humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT manatotanaka humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT moekawashima humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT yunauchi humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT jojishindo humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT tomoyoshioikawa humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT kenjishibuya humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT tatsuhikokodama humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey AT masaharutsubokura humoralimmunityafterseconddoseofbnt162b2vaccineinjapanesecommunitiesanobservationalcrosssectionalstudyfukushimavaccinationcommunitysurvey |